 A new type of prophylactic vaccine has been developed which can rapidly control multiple types of viruses, including SARS-CoV-2, RSV, and influenza. This glycolipid, called 7DW8-5, works by binding to CD1D receptors on antigen-presenting cells and activating NKT cells, which then produce a cascade of cytokines and chemokines that help fight off the virus. This approach is effective against multiple viruses and does not require any pre-existing immunity. It could potentially be used to quickly control outbreaks of viruses such as SARS-CoV-2, RSV, and influenza, even before vaccines or drugs are available. This article was authored by Maria Seiji, Manoj Esne, Kozio Masuda, and others.